BioNTech to cut fifth of workforce as it winds down Covid vaccine production https://t.co/yfbpiIVKq1

BioNTech, the pioneering biotech firm that collaborated with Pfizer to produce one of the first Covid-19 vaccines, is set to reduce its workforce by 20% as it scales back vaccine production. As the global demand for Covid vaccines diminishes, the company is adjusting its operations to align with the changing market dynamics. This strategic shift marks a significant transition for BioNTech, which experienced rapid expansion during the pandemic. The company aims to redirect resources towards developing new therapies and expanding its oncology pipeline, signaling a broader focus beyond infectious diseases. This move underscores the ongoing evolution within the pharmaceutical industry as it adapts to post-pandemic realities.